ClinicalTrials.gg
CompletedNCT01683071Updated Dec 9, 2020Results posted

Femoral Nerve Block With Liposome Bupivacaine for Postsurgical Analgesia Following Total Knee Arthroplasty

A Phase 2/3 interventional study of Placebo and EXPAREL 67 mg in Postoperative Pain, sponsored by Pacira Pharmaceuticals, Inc. Completed at 30 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-09.

Sponsored by Pacira Pharmaceuticals, Inc · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
297
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 93 studies testing Liposomal Bupivacaine in Pain, Postoperative — 14 open to participants now, 15 under way, 2 of them phase 3. Liposomal Bupivacaine · Pain, Postoperative.

Enrollment
3rd of 93
297 · median 80
Started
2012
with 5 others
Phase 2/3
5 of 93
2 open now
Registered
2nd of 93
by date
Lead sponsor
11 of 93
Pacira Pharmaceuticals, Inc

Among the 93 studies testing Liposomal Bupivacaine in Pain, Postoperative, this one is the 3rd largest by enrollment, is one of 6 that started in 2012, is one of 5 in phase 2/3, and was the 2nd registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

14 of the 93 studies testing Liposomal Bupivacaine in Pain, Postoperative are open now, in 3 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About Liposomal Bupivacaine

Liposomal Bupivacaine: first FDA approval 2011 (EXPAREL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies testing Liposomal Bupivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

The primary objectives of Part 1 are to (1) evaluate three dose levels of liposome bupivacaine versus placebo with respect to the magnitude and duration of the analgesic effect achieved following single dose injection femoral nerve block with liposome bupivacaine, and (2) select a single therapeutic dose of liposome bupivacaine from the three dose levels to be tested in Part 2.

Part 2: The primary objective of Part 2 is to compare the magnitude and duration of the analgesic effect of single injection femoral nerve block of a single dose level of liposome bupivacaine (selected from Part 1) with placebo (preservative-free normal saline).

Read the detailed description

This is a Phase 2/3, multicenter, randomized, double-blind, parallel-group, placebo-controlled, dose-ranging study in subjects undergoing primary unilateral total knee arthroplasty (TKA) under general or spinal anesthesia. Note: Bupivacaine cannot be used as the spinal anesthetic.

Part 1 During Part 1 of the study, approximately 100 subjects (25 per treatment arm) will be randomized to receive a single dose injection femoral nerve block with either one of three doses of liposome bupivacaine (67, 133, or 266 mg) or placebo in 20 mL under ultrasound guidance. Preservative-free normal saline will be added to the 67 mg and 133 mg doses of study drug to achieve a volume of 20 mL.

Part 2 In Part 2 of the study, approximately 180 subjects (randomized 1:1, resulting in approximately 90 liposome bupivacaine subjects and 90 placebo subjects) will receive a single dose injection femoral nerve block with the selected dose level of liposome bupivacaine (i.e., 67, 133, or 266 mg) or placebo in 20 mL under ultrasound guidance.

03

Conditions studied

  • Postoperative Pain

Browse trials for

Keywords

  • Total knee arthroplasty
  • Analgesia
  • Pain management
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, >=18 years of age.
  2. Scheduled to undergo primary unilateral TKA under general or spinal anesthesia.
  3. (ASA) Physical Status 1, 2, or 3.
  4. Able to demonstrate motor function by performing a 20-meter walk, unassisted with the optional use of a 4-legged walker, and sensory function by exhibiting sensitivity to cold.
  5. Able to provide , adhere to the study visit schedule, and complete all study assessments.

Exclusion criteria

Exclusion Criteria:

  1. Currently pregnant, nursing, or planning to become pregnant during the study or within 1 month after study drug administration. Female subjects must be surgically sterile, at least 2 years menopausal, or using an acceptable method of .

    If of , must have a documented negative pregnancy test within 24 hours before surgery.

  2. Planned concurrent surgical procedure (e.g., bilateral TKA).
  3. Use of any of the following medications within the times specified before surgery:

    long-acting opioid medication, NSAIDs, aspirin (except for low-dose aspirin used for cardioprotection) or acetaminophen within 3 days, or and any opioid medication within 24 hours.

  4. Concurrent painful physical condition or concurrent surgery that may require analgesic treatment (such as an NSAID or opioid) in the postsurgical period for pain that is not strictly related to the surgical site administered study treatment, and which may confound the postsurgical assessments (e.g., significant pain from other joints including the non-index knee joint, chronic neuropathic pain, prior contralateral TKA, concurrent foot surgery).
  5. Initiation of treatment with any of the following medications within 1 month of study drug administration or if the medication(s) are being given to control pain: selective serotonin reuptake inhibitors (SSRIs), selective norepinepherine reuptake inhibitors (SNRIs), gabapentin, pregabalin (Lyrica®), or duloxetine (Cymbalta®).
  6. Current use of systemic glucocorticosteroids within 1 month of enrollment in this study.
  7. Body weight \< 50 kilograms (110 pounds) or a ≥ 40 kg/m2.
  8. to hydromorphone, oxycodone, or bupivacaine.
  9. Administration of an drug within 30 days or 5 elimination half-lives of such investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study.
  10. Previous participation in a liposome bupivacaine study.
  11. History of, suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years.
  12. Failure to pass the urine drug screen.
  13. Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the Investigator, could interfere with study assessments or compliance.
  14. in the last 2 years, with the exception of non- basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.
  15. Current or historical evidence of any disease or condition, especially cardiovascular or neurological conditions that, in the opinion of the Investigator, may increase the risk of surgery or complicate the subject's postsurgical course.
  16. Significant medical conditions or laboratory results that, in the opinion of the Investigator, indicate an increased vulnerability to study drugs and procedures.
  17. Subjects who are planned to receive Entereg® (alvimopan).
  18. Subjects who will receive prophylactic antiemetics or planned postsurgical antiemetics given without regard to the subject's emesis needs.
  19. Use of dexmedetomidine HCl (Precedex®) within 3 days of surgery.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
297 participants (actual)

Study arms

  • Experimental
    (Part 1) EXPAREL 67 mg

    5 mL EXPAREL (bupivacaine liposome injectable suspension) expanded with 15 mL normal saline as single-injection femoral nerve block ≤2 h preoperatively

    Drug: EXPAREL 67 mg

  • Experimental
    (Part 1) EXPAREL 133 mg

    10 mL EXPAREL (bupivacaine liposome injectable suspension) expanded with 10 mL normal saline as single-injection femoral nerve block ≤2 h preoperatively

    Drug: EXPAREL 133 mg

  • Experimental
    (Part 1) EXPAREL 266 mg

    20 mL EXPAREL (bupivacaine liposome injectable suspension) as single-injection femoral nerve block ≤2 h preoperatively

    Drug: EXPAREL 266 mg

  • Placebo comparator
    (Part 1) Placebo

    20 mL normal saline as single-injection femoral nerve block ≤2 h preoperatively

    Drug: Placebo

  • Experimental
    (Part 2) EXPAREL 266 mg

    20 mL EXPAREL (bupivacaine liposome injectable suspension) as single-injection femoral nerve block ≤2 h preoperatively

    Drug: EXPAREL 266 mg

  • Placebo comparator
    (Part 2) Placebo

    20 mL normal saline as single-injection femoral nerve block ≤2 h preoperatively

    Drug: Placebo

Interventions

  • DrugPlacebo

    Normal saline 20 mL as single-injection femoral nerve block prior to total knee arthroplasty

    Also known as: Preservative-free normal saline.

  • 5 mL EXPAREL expanded with 15 mL normal saline as single-injection femoral nerve block prior to total knee arthroplasty

    Also known as: Bupivacaine liposome injectable suspension 67 mg/5 mL

  • 10 mL EXPAREL expanded with 10 mL normal saline as single-injection femoral nerve block prior to total knee arthroplasty

    Also known as: Bupivacaine liposome injectable suspension 133 mg/10 mL

  • 20 mL EXPAREL as single-injection femoral nerve block prior to total knee arthroplasty

    Also known as: Bupivacaine liposome injectable suspension 266 mg/20 mL

06

What researchers measure

Primary outcomes

  1. Area Under the Curve (AUC) of Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores Through 72 Hours

    AUC of NRS-R pain intensity scores through 72 hours. Pain intensity scores were measured on an 11-point NRS (0=no pain and 10=worst possible pain)

    Time frame: 0-72 hours

Secondary outcomes

  1. Total Postsurgical Opioid Consumption Through 72 Hours

    Total postsurgical opioid consumption of opioid rescue pain medication (converted to IV morphine equivalents) through 72 hours

    Time frame: 0-72 hours

  2. Time to First Opioid Rescue Through 72 Hours

    Time to first opioid rescue medication consumed through 72 hours

    Time frame: 0-72 hours

07

Results

Posted Dec 9, 2020

Participant flow

Participants were recruited between September 24, 2012 and December 20, 2013 at 23 sites in the US

Part 1
Participant flow — Part 1
Milestone(Part 1) EXPAREL 67 mg(Part 1) EXPAREL 133 mg(Part 1) EXPAREL 266 mg(Part 1) Placebo(Part 2) EXPAREL 266 mg(Part 2) Placebo
Started2526252500
Completed2122222000
Not completed443500
Withdrew: Lack of efficacy100300
Withdrew: Withdrawal by subject122100
Withdrew: Surgery cancelled100000
Withdrew: Did not receive study drug100100
Withdrew: Early termination; met exclusion criteria021000
Part 2
Participant flow — Part 2
Milestone(Part 1) EXPAREL 67 mg(Part 1) EXPAREL 133 mg(Part 1) EXPAREL 266 mg(Part 1) Placebo(Part 2) EXPAREL 266 mg(Part 2) Placebo
Started00009997
Completed00008282
Not completed00001715
Withdrew: Lack of efficacy000034
Withdrew: Lost to follow-up000020
Withdrew: Withdrawal by subject000033
Withdrew: Surgery cancelled000042
Withdrew: Did not receive study drug000021
Withdrew: Met exclusion criterion000011
Withdrew: Protocol deviation000012
Withdrew: Withdrawal by investigator decision000012

Outcome measures

PrimaryArea Under the Curve (AUC) of Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores Through 72 Hours

AUC of NRS-R pain intensity scores through 72 hours. Pain intensity scores were measured on an 11-point NRS (0=no pain and 10=worst possible pain)

Time frame:
0-72 hours
Reported as:
Least squares mean · score on a scale * hr
Area Under the Curve (AUC) of Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores Through 72 Hours
score on a scale * hr(Part 1) EXPAREL 67 mg(Part 1) EXPAREL 133 mg(Part 1) EXPAREL 266 mg(Part 1) Placebo(Part 2) EXPAREL 266 mg(Part 2) Placebo
Area Under the Curve (AUC) of Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores Through 72 Hours533.4 ± 33.15427.2 ± 31.73436.2 ± 31.79530.5 ± 31.73418.9 ± 16.86515.5 ± 16.95
Statistical analysis
  • (Part 1) EXPAREL 67 mg vs (Part 1) Placebo · ANCOVA · p = 0.9494 · Lsmd: 2.9 · 95% CI -88 to 94
  • (Part 1) EXPAREL 133 mg vs (Part 1) Placebo · ANCOVA · p = 0.0237 · Lsmd: -103.3 · 95% CI -192 to -14
  • (Part 1) EXPAREL 266 mg vs (Part 1) Placebo · ANCOVA · p = 0.0386 · Lsmd: -94.3 · 95% CI -184 to -5
  • (Part 2) EXPAREL 266 mg vs (Part 2) Placebo · ANCOVA · p = <0.0001 · Lsmd: -96.5 · 95% CI -144 to -49
SecondaryTotal Postsurgical Opioid Consumption Through 72 Hours

Total postsurgical opioid consumption of opioid rescue pain medication (converted to IV morphine equivalents) through 72 hours

Time frame:
0-72 hours
Reported as:
Mean · mg morphine equivalents
Total Postsurgical Opioid Consumption Through 72 Hours
mg morphine equivalents(Part 1) EXPAREL 67 mg(Part 1) EXPAREL 133 mg(Part 1) EXPAREL 266 mg(Part 1) Placebo(Part 2) EXPAREL 266 mg(Part 2) Placebo
Total Postsurgical Opioid Consumption Through 72 Hours126.69 ± 75.972100.35 ± 53.177105.96 ± 53.402124.78 ± 58.74393.19 ± 58.133122.08 ± 70.312
Statistical analysis
  • (Part 1) EXPAREL 67 mg vs (Part 1) Placebo · ANOVA · p = 0.6182 · Geometric lsm ratio: 0.90 · 95% CI 0.6 to 1.3
  • (Part 1) EXPAREL 133 mg vs (Part 1) Placebo · ANOVA · p = 0.1097 · Geometric lsm ratio: 0.73 · 95% CI 0.5 to 1.1
  • (Part 1) EXPAREL 266 mg vs (Part 1) Placebo · ANOVA · p = 0.4046 · Geometric lsm ratio: 0.85 · 95% CI 0.6 to 1.3
  • (Part 2) EXPAREL 266 mg vs (Part 2) Placebo · ANOVA · p = 0.0016 · Geometric lsm ratio: 0.74 · 95% CI 0.6 to 0.9
SecondaryTime to First Opioid Rescue Through 72 Hours

Time to first opioid rescue medication consumed through 72 hours

Time frame:
0-72 hours
Reported as:
Median · hours
Time to First Opioid Rescue Through 72 Hours
hours(Part 1) EXPAREL 67 mg(Part 1) EXPAREL 133 mg(Part 1) EXPAREL 266 mg(Part 1) Placebo(Part 2) EXPAREL 266 mg(Part 2) Placebo
Time to First Opioid Rescue Through 72 Hours0.49 (0.300 to 0.650)0.37 (0.283 to 0.700)1.29 (0.367 to 2.350)0.41 (0.300 to 0.550)0.44 (0.400 to 0.533)0.43 (0.367 to 0.567)

Adverse events

Collected over From screening through postsurgical day 30. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
(Part 1) EXPAREL 67 mg0/22 (0%)4/22 (18.2%)19/22 (86.4%)
(Part 1) EXPAREL 133 mg0/24 (0%)2/24 (8.3%)20/24 (83.3%)
(Part 1) EXPAREL 266 mg0/24 (0%)1/24 (4.2%)21/24 (87.5%)
(Part 1) Placebo0/24 (0%)3/24 (12.5%)21/24 (87.5%)
(Part 2) EXPAREL 266 mg0/92 (0%)8/92 (8.7%)82/92 (89.1%)
(Part 2) Placebo0/92 (0%)9/92 (9.8%)83/92 (90.2%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
Event(Part 1) EXPAREL 67 mg(Part 1) EXPAREL 133 mg(Part 1) EXPAREL 266 mg(Part 1) Placebo(Part 2) EXPAREL 266 mg(Part 2) Placebo
AnemiaBlood and lymphatic system disorders2/220/241/240/241/922/92
CellulitisInfections and infestations1/220/240/240/240/920/92
Wound DehiscenceInjury, poisoning and procedural complications1/220/240/241/240/920/92
Liver function test abnormalInvestigations1/220/240/240/240/920/92
Acute Prerenal FailureRenal and urinary disorders1/220/240/240/240/920/92
Deep Vein ThrombosisVascular disorders1/220/240/240/240/920/92
PyrexiaGeneral disorders0/220/240/240/244/921/92
Device Related InfectionInfections and infestations0/220/240/241/240/920/92
Wound InfectionInfections and infestations0/220/240/241/240/921/92
Wound DecompositionInjury, poisoning and procedural complications0/220/240/241/240/920/92
Most frequent other events
Showing 10 of 25
Most frequent other events
Event(Part 1) EXPAREL 67 mg(Part 1) EXPAREL 133 mg(Part 1) EXPAREL 266 mg(Part 1) Placebo(Part 2) EXPAREL 266 mg(Part 2) Placebo
NauseaGastrointestinal disorders8/2214/2413/249/2449/9261/92
VomitingGastrointestinal disorders1/220/241/242/2426/9238/92
PyrexiaGeneral disorders8/227/248/243/2428/9224/92
PruritisSkin and subcutaneous tissue disorders1/222/242/242/2433/9231/92
ConstipationGastrointestinal disorders3/222/246/241/2432/9232/92
DizzinessNervous system disorders3/223/244/246/2415/9219/92
AnaemiaBlood and lymphatic system disorders4/221/244/242/248/925/92
InsomniaPsychiatric disorders1/222/242/244/245/9211/92
Urinary RetentionRenal and urinary disorders1/220/240/240/2412/926/92
HeadacheNervous system disorders1/223/242/241/245/924/92

Baseline characteristics

Safety population included all participants who received study drug, with analysis by actual treatment received.

Age, Continuous
Age, Continuous(years)(Part 1) EXPAREL 67 mg(Part 1) EXPAREL 133 mg(Part 1) EXPAREL 266 mg(Part 1) Placebo(Part 2) EXPAREL 266 mg(Part 2) PlaceboTotal
Mean68.5 ± 8.4165.7 ± 7.3066.4 ± 8.9466.1 ± 12.1766.4 ± 10.3563.6 ± 8.7665.0 ± 9.67
Sex: Female, Male
Sex: Female, Male(Participants)(Part 1) EXPAREL 67 mg(Part 1) EXPAREL 133 mg(Part 1) EXPAREL 266 mg(Part 1) Placebo(Part 2) EXPAREL 266 mg(Part 2) PlaceboTotal
Female81614145257161
Male14810104035117
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)(Part 1) EXPAREL 67 mg(Part 1) EXPAREL 133 mg(Part 1) EXPAREL 266 mg(Part 1) Placebo(Part 2) EXPAREL 266 mg(Part 2) PlaceboTotal
Hispanic or Latino11238924
Not Hispanic or Latino212322218483254
Unknown or Not Reported0000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)(Part 1) EXPAREL 67 mg(Part 1) EXPAREL 133 mg(Part 1) EXPAREL 266 mg(Part 1) Placebo(Part 2) EXPAREL 266 mg(Part 2) PlaceboTotal
American Indian or Alaska Native0000011
Asian1010204
Native Hawaiian or Other Pacific Islander0000000
Black or African American1224151438
White202221207576234
More than one race0000011
Unknown or Not Reported0000000
Region of Enrollment
Region of Enrollment(participants)(Part 1) EXPAREL 67 mg(Part 1) EXPAREL 133 mg(Part 1) EXPAREL 266 mg(Part 1) Placebo(Part 2) EXPAREL 266 mg(Part 2) PlaceboTotal
United States222424249292278
American Society of Anesthesiologists (ASA) classification
American Society of Anesthesiologists (ASA) classification(Participants)(Part 1) EXPAREL 67 mg(Part 1) EXPAREL 133 mg(Part 1) EXPAREL 266 mg(Part 1) Placebo(Part 2) EXPAREL 266 mg(Part 2) PlaceboTotal
100107311
2111613153849142
31181094740125
>/= 40000000
Type of Anesthesia
Type of Anesthesia(Participants)(Part 1) EXPAREL 67 mg(Part 1) EXPAREL 133 mg(Part 1) EXPAREL 266 mg(Part 1) Placebo(Part 2) EXPAREL 266 mg(Part 2) PlaceboTotal
General151712216256183
Spinal67123283591
Other1000203
Duration of Surgery
Duration of Surgery(minutes)(Part 1) EXPAREL 67 mg(Part 1) EXPAREL 133 mg(Part 1) EXPAREL 266 mg(Part 1) Placebo(Part 2) EXPAREL 266 mg(Part 2) PlaceboTotal
Mean85.8 ± 25.5388.5 ± 27.9696.0 ± 37.9485.0 ± 35.5394.1 ± 34.4394.9 ± 37.5494.5 ± 35.9

1 further baseline measures are reported on the registry.

08

Study locations

30 sites
  • ACHIEVE CLINICAL RESEARCH LLC 2017 Canyon Road Suite 41
    Birmingham, Alabama 35216, United States
  • HORIZON RESEARCH GROUP INC 3610 Springhill Memorial Dr. N
    Mobile, Alabama 36608, United States
  • Veritas Research, LLC
    Mobile, Alabama 36660, United States
  • SHOALS MEDICAL TRIALS INC. 1300 S Montgomery Ave
    Sheffield, Alabama 35660, United States
  • PHOENIX ORTHOPAEDIC SURGEONS 2525 W. Greenway Road Suite 114
    Phoenix, Arizona 85023, United States
  • ALLIANCE RESEARCH CENTERS 24411 Health Center Drive Suite 350
    Laguna Hills, California 92653, United States
  • ORTHOPADIC SURGERY Loma Linda University Health Care Dept. Pf Orthopaedic Surgery 250 East Caroline Street Suite A
    San Bernardino, California 92508, United States
  • University of California, San Diego
    San Diego, California 92103, United States
  • Ilfeld, Brian (Thornton) UNIVERSITY OF CALIFORNIA, SAN DIEGO 10610 Hunters Glen Drive
    San Diego, California 92130, United States
  • FLORIDA RESEARCH ASSOCIATES, LLC / FLORIDA ORTHOPAEDIC ASSOCIATES 740 W. Plymouth Ave
    DeLand, Florida 32720, United States
  • JACKSON MEMORIAL HOSPITAL UNVERSITY OF MIAMI 1611 Nw. 12th Ave C300
    Miami, Florida 33136, United States
  • PENSACOLA RESEARCH CONSULTANTS,INC 5149 N.9th Avenue Suite 241
    Pensacola, Florida 32504, United States
  • SHERIDAN CLINICAL RESEARCH, INC. 1613 N. Harrison Parkway Building C Suite 200
    Sunrise, Florida 33323, United States
  • PHOENIX CLINICAL RESEARCH,LLC 7171 N. University Drive Suite 100
    Tamarac, Florida 33321, United States
  • UNIVERSITY OF KANSAS HOSPITAL & MEDICAL CENTER Dept. Of Anesthesiology 3901 Rainbow Blvd. Ms 1034
    Kansas City, Kansas 66160, United States
  • BEAUMONT HEALTH SYSTEM 44201 Dequindre Road Suite Pob 120
    Troy, Michigan 48085, United States
  • COOPER UNIVERSITY HOSPITAL 1 Cooper Plaza 202 Dorrance Building
    Camden, New Jersey 08103, United States
  • UNIVERSITY OF MEDICINE AND DENSITRY OF NEW JERSEY/NEW JERSEY MEDICAL SCHOOL 185 South Orange Ave. Department of Anesthesiology - MSB E538
    Newark, New Jersey 07101, United States
  • NORTHERN WESTCHESTER HOSPTIAL Department Of Clinical Trials 400 East Main St.
    Mount Kisco, New York 10549, United States
  • ST. LUKE-ROOSEVELT HOSPITAL CENTER Dept. Of Anesthesiology 1111 Amsterdam Ave. Travis Bld. 7
    New York, New York 10025, United States
  • INSALL-SCOTT-KELLY INSTITUTE 210 East 64th Street
    New York, New York 10065, United States
  • UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL Department Of Anesthesiology 101 Manning Drive N0021, Cb 7010
    Chapel Hill, North Carolina 27599, United States
  • CLEVELAND CLINIC FAIRVIEW HOSPTIAL 1801 Lorain Avenue
    Cleveland, Ohio 44111, United States
  • CLEVELAND CLINIC 9500 Euclid Ave P-77
    Cleveland, Ohio 44195, United States
  • PENN STATE MILTON S. HERSHEY MEDICAL CENTER H187,500 University Drive
    Hershey, Pennsylvania 17033, United States
  • THOMAS JEFFERSON UNIVERSITY Dept. Of Anesthesiology 111 S. 11th Street Suite G 8490
    Philadelphia, Pennsylvania 19107, United States
  • UPMC PRESBYTERIAN SHADYSIDE/ DEPT. OF ANESTHESIOLOGY POSNER PAIN CENTER 532 South Aiken Avenue Suite 407
    Pittsburgh, Pennsylvania 15232, United States
  • UNIVERSITY OF TEXAS MEDICAL BRANCH Dept. Chairman, Orthopedic Surgery & Rehabilitation 2.316 Rebecca Sealy Hospital 301 University Blvd.
    Galveston, Texas 77551, United States
  • RESEARCH CONCEPTS,GP LLC 921 Gessner Rd. Anesthesia Dept., Classroom F
    Houston, Texas 77024, United States
  • CHRISTUS ST. JOHN HOSPITAL 18300 St. John Dr., 2nd Floor, Surgery
    Nassau Bay, Texas 77058, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2020, 7 years after primary completion. A results delay was requested in Mar 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2012
First posted
Sep 11, 2012
Start
Sep 2012
Primary completionActual
Dec 2013
CompletionActual
Dec 2013
Results delay requested
Mar 24, 2014
Results first posted
Dec 9, 2020
Last update
Dec 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01683071
Responsible party
Sponsor
First posted
Sep 11, 2012
Start date
Sep 2012
Primary completion
Dec 2013
Completion
Dec 2013
Results posted
Dec 9, 2020
Last update
Dec 9, 2020

Study contacts

Erol Onel, MD
study director · Pacira Pharmaceuticals, Inc

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal Bupivacaine

Start the discussion